{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "1289359",
  "DateCompleted": {
    "Year": "1993",
    "Month": "03",
    "Day": "25"
  },
  "DateRevised": {
    "Year": "2019",
    "Month": "05",
    "Day": "09"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0305-7453",
      "JournalIssue": {
        "Volume": "30",
        "Issue": "6",
        "PubDate": {
          "Year": "1992",
          "Month": "Dec"
        }
      },
      "Title": "The Journal of antimicrobial chemotherapy",
      "ISOAbbreviation": "J Antimicrob Chemother"
    },
    "ArticleTitle": "A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies.",
    "Pagination": {
      "StartPage": "843",
      "EndPage": "854",
      "MedlinePgn": "843-54"
    },
    "Abstract": {
      "AbstractText": [
        "Three-hundred and twelve episodes of fever in 234 neutropenic patients with haematological malignancies were treated empirically with either imipenem or a combination of piperacillin and gentamicin. There were no significant differences in the percentages of patients responding to therapy at either 72 h (59% and 56% of assessable episodes in the imipenem and combination groups respectively) or at the end of treatment (55% and 53% of assessable episodes in the imipenem and combination groups respectively). Patients in the piperacillin plus gentamicin group experienced significantly more renal tubular damage whereas those who received imipenem suffered more nausea or vomiting. We conclude that imipenem monotherapy represents an acceptable alternative to piperacillin plus gentamicin as empirical therapy of the febrile neutropenic patient."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Haematology, East Birmingham Hospital, UK."
          }
        ],
        "LastName": "Leyland",
        "ForeName": "M J",
        "Initials": "MJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Bayston",
        "ForeName": "K F",
        "Initials": "KF"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Cohen",
        "ForeName": "J",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Warren",
        "ForeName": "R",
        "Initials": "R"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Newland",
        "ForeName": "A C",
        "Initials": "AC"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Bint",
        "ForeName": "A J",
        "Initials": "AJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Cefai",
        "ForeName": "C",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "White",
        "ForeName": "D G",
        "Initials": "DG"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Murray",
        "ForeName": "S A",
        "Initials": "SA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Bareford",
        "ForeName": "D",
        "Initials": "D"
      }
    ],
    "PublicationTypeList": [
      "Clinical Trial",
      "Comparative Study",
      "Journal Article",
      "Multicenter Study",
      "Randomized Controlled Trial",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "J Antimicrob Chemother",
    "NlmUniqueID": "7513617",
    "ISSNLinking": "0305-7453"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Gentamicins"
    },
    {
      "RegistryNumber": "71OTZ9ZE0A",
      "NameOfSubstance": "Imipenem"
    },
    {
      "RegistryNumber": "X00B0D5O0E",
      "NameOfSubstance": "Piperacillin"
    }
  ],
  "CommentsCorrectionsList": [
    {
      "RefSource": "J Antimicrob Chemother 1993 Apr;31(4):621"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adolescent"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aged"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Drug Therapy, Combination"
    },
    {
      "QualifierName": [
        "drug therapy",
        "etiology",
        "microbiology"
      ],
      "DescriptorName": "Fever"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Gentamicins"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Imipenem"
    },
    {
      "QualifierName": [
        "complications"
      ],
      "DescriptorName": "Leukemia"
    },
    {
      "QualifierName": [
        "complications"
      ],
      "DescriptorName": "Lymphoma"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [
        "complications",
        "etiology"
      ],
      "DescriptorName": "Neutropenia"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Piperacillin"
    }
  ]
}